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S U M M A R Y
Background: Some studies done in Asian patients have shown that serum levels of hepatitis B virus (HBV)
DNA predict the development of cirrhosis. However, it is unclear whether this also applies for non-Asian
patients. This study investigated historic and current HBV DNA and quantitative hepatitis B surface
antigen (HBsAg) levels as predictors of cirrhosis in non-Asian women with chronic HBV.
Methods: A retrospective cohort study of non-Asian women with chronic HBV was performed. Among
other variables, HBV DNA and quantitative HBsAg levels were measured in stored historic serum samples
obtained during pregnancy (period 1990–2004) and current serum samples (period 2011–2012) to
determine any association with liver cirrhosis by liver stiffness measurement (LSM).
Results: One hundred and nineteen asymptomatic, treatment-naı¨ve non-Asian women were included;
the median number of years between the historic sample and the current sample was 17 (interquartile
range (IQR) 13–20). The median historic log HBV DNA and quantitative log HBsAg levels were 2.5 (IQR
1.9–3.4) IU/ml and 4.2 (IQR 3.6–4.5) IU/ml, respectively. LSM diagnosed 14 patients (12%) with F3–F4
ﬁbrosis, i.e. stiffness >8.1 kPa. No association of cirrhosis was found with historic HBV DNA (relative risk
(RR) 0.34, 95% conﬁdence interval (CI) 0.05–2.44) or with the quantitative HBsAg level (HBsAg level
>1000 IU/ml, RR 0.35, 95% CI 0.11–1.11). Multivariable analysis identiﬁed alcohol consumption (odds
ratio (OR) 6.4, 95% CI 1.3–30.1), aspartate aminotransferase >0.5 times the upper limit of normal (OR
15.4, 95% CI 1.9–122.6), and prothrombin time (OR 12.0, 95% CI 1.2–120.4), but not HBV DNA or
quantitative HBsAg level, to be independent predictors of the presence of cirrhosis.
Conclusions: Neither historic nor current HBV DNA or the quantitative HBsAg level is associated with the
development of HBV-related cirrhosis in non-Asian women.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Liver cirrhosis with the risk of developing hepatocellular
carcinoma (HCC) is an increasing clinical problem in patients
infected with hepatitis B virus (HBV).1 In recent years, HBV DNA* Corresponding author. Tel.: +31 (0)88 7555555; fax: +31 (0)30 2523741.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).has been identiﬁed as an important predictor of the development
of HBV-related liver disease.2–9 Studies from the REVEAL-HBV
group have shown a clear association between serum HBV DNA
and the development of both cirrhosis and HCC in Taiwanese HBV-
infected patients.4,5 This has resulted in a greater emphasis being
placed on HBV DNA measurement in international hepatitis B
guidelines.10–12
Asian people may differ in viral and host factors from those
originating from other regions of the world.13 For instance, HBVciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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genotypes A and D predominate in northern Europe14, and Asian
patients have different cardiovascular risk factors.15
Given these viral and host differences, the role of HBV DNA in
the progression of liver ﬁbrosis may also differ between Asian
patients and those of other populations. Therefore, we investigat-
ed, amongst other variables, the association between HBV DNA and
the development of liver cirrhosis in non-Asian patients with
chronic HBV.
2. Materials and methods
2.1. Patients and study design
HBV is a notiﬁable disease in the Netherlands. The blood
samples of women from Amsterdam who were diagnosed with
chronic HBV during pregnancy (hepatitis B surface antigen
(HBsAg)-positive) between 1990 and 2004 were stored at the
Public Health Service Amsterdam (historic samples). Criteria for
chronic HBV infection were the following: persistent HBsAg
positivity during the 6 months after diagnosis, or an already
known chronic HBV patient, or a history during source and contact
tracing without factors associated with a recent infection. Between
September 2011 and May 2012 these women with chronic HBV
infections were invited to provide a short history and undergo a
physical examination focusing on symptoms of chronic liver
disease, liver stiffness measurement (LSM), and additional blood
tests (current sample).
Women with an HIV or hepatitis C co-infection, those younger
than 18 years of age, those with parents or ancestors of Asian
descent, those receiving HBV therapy, and those who could not
give informed consent were excluded from the study. Hepatitis D
virus (HDV) was only tested in patients with moderate to severe
ﬁbrosis (F2 or more).
All patients provided written informed consent and the study
was conducted in accordance with the Declaration of Helsinki and
the International Conference on Harmonization Guidelines for
Good Clinical Practice, with the approval of the local medical ethics
committee of the Academic Medical Centre Amsterdam. The study
is registered with ClinicalTrials.gov (number NCT01462981).
2.2. Liver stiffness measurement
LSM was performed with a FibroScan device (model F402;
Echosens, France) by an experienced researcher (SH), according to
standard operating procedures, as described previously.16 A valid
LSM was deﬁned as at least 10 valid measurements, a success rate
of at least 60%, and an interquartile range (IQR) less than 33% of the
median stiffness. The extent of ﬁbrosis was staged according to the
METAVIR classiﬁcation for HBV,17 with F0/F1 <7.2 kPa, F2 between
7.2 and 8.0 kPa, F3 between 8.1 and 11.0 kPa, and F4
>11.0 kPa.18,19
2.3. Laboratory tests
Biochemical parameters for the assessment of liver function
(total bilirubin, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), gamma-glutamyl transferase (GGT), alkaline
phosphatase (ALP), and prothrombin time) together with renal
(blood urea nitrogen, creatinine) and haematological parameters
(haemoglobin, leucocytes, thrombocytes) and alpha-fetoprotein
(AFP), were determined using local standard laboratory proce-
dures. All of these parameters were measured only in the current
blood sample. The cut-off values of ALT and AST for women were
30 IU/L and 35 IU/L, respectively.HBV DNA and quantitative HBsAg levels were determined in
both the historic sample and the current sample. HBV DNA was
determined by COBAS TaqMan (Roche, Meylan, France) with a
lower detection limit of 20 IU/ml. Qualitative and quantitative
analyses of HBsAg, hepatitis C virus antibodies (anti-HCV), and
HIV antibodies (anti-HIV) were performed with the ADVIA Centaur
XP assay (Siemens, Erlangen, Germany). The quantitative HBsAg
level assay had a detection limit of 1 IU/ml. The assessment of
hepatitis B e antigen (HBeAg) was performed with the AxSYM
Immunochemical Automated Analyzer (Abbott, Illinois, USA) and
the assessment of HDV antibodies (anti-HDV) was performed with
a qualitative ELISA, the ETI-AB-Deltak-2 (DiaSorin S.p.A., Turin,
Italy). HBV genotype was determined by COBAS Ampliprep/COBAS
TaqMan HBV test 2.0 (Roche, Meylan, France). The genotype could
only be determined in patients with an HBV DNA of 1000 IU/ml or
higher.
2.4. Statistical analysis
The sample size calculation was based on a 5.5% prevalence rate
of liver cirrhosis in the low viral DNA group (HBV DNA <104 IU/ml)
and 23.4% in the high viral DNA group (HBV DNA >104 IU/ml), as
reported by the REVEAL-HBV study group.5 The calculated sample
size was 172 patients, with the assumption of a difference in
prevalence rate of cirrhosis of 10% between the low viral DNA
group (HBV DNA level <20 000 IU/ml) and the high viral DNA
group (HBV DNA level >20 000 IU/ml), 80% power at the 5%
signiﬁcance level, and a 3-to-1 allocation to the low viral DNA
group. With an estimated refusal rate of 50%, a total of at least
344 patients had to be contacted.
To analyze the association between HBV DNA and cirrhosis,
HBV DNA was classiﬁed according to the four viral DNA groups
deﬁned by the European Association for the Study of the Liver
(EASL) guidelines.12 These four HBV DNA groups are: undetectable
(HBV DNA <20 IU/ml), low (HBV DNA 20–2000 IU/ml), intermedi-
ate (HBV DNA 2000–20 000 IU/ml), and high viral DNA (HBV DNA
>20 000 IU/ml). The quantitative HBsAg level was also divided into
two groups (below and above 1000 IU/ml) in accordance with the
EASL guidelines.12
Continuous variables were summarized as the median with IQR
and categorical variables as the frequency with the percentage. The
HBV DNA and quantitative HBsAg levels were expressed logarith-
mically. Differences between two groups were calculated with the
Mann–Whitney U-test for continuous variables and the Chi-square
test for categorical variables. The historic data were analyzed with
univariable and multivariable Poisson regression models with time
adjustment for variable follow-up. Outcomes were reported as
relative risks (RR) with 95% conﬁdence intervals (CI). The data from
the study visit were analyzed with univariable and multivariable
logistic regression models. Outcomes were reported as odds ratios
(OR) with 95% CI. A p-value of <0.05 was considered signiﬁcant.
The statistical analysis was performed with SPSS v. 17 (SPSS Inc.,
Chicago, IL, USA) and Stata 11 (StataCorp LP, College Station, TX,
USA).
3. Results
3.1. Patient characteristics
Of 1113 women with stored blood samples, 376 were eligible
for this study, of whom a total of 174 consented to participate
(Figure 1). After the exclusion of 55 patients, mainly because of
inconclusive LSM results, the data of 119 women were included in
the ﬁnal analysis. The patient characteristics are given in
Table 1. Of the known HBV genotypes, D was the most prevalent
(46%). The percentages of HBeAg-positive women in the historic
Figure 1. Flowchart summarizing the process of patient selection.
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women had increased ALT levels, at 54 and 78 IU/l. The median
follow-up time between pregnancy screening and the study visit
was 17 (IQR 13–20) years.
We explored whether patients with an inconclusive LSM
(47 patients) were different from the main study population
(119 patients), leading to a bias in study results. There was no
difference with regard to age at pregnancy screening, or in historic
and current HBV DNA and quantitative HBsAg levels (data not
shown). However, the excluded patients had a higher body mass
index (BMI; median 32 (IQR 28–37) vs. 29 (IQR 26–32) kg/m2; p <
0.001) and a slightly longer time between pregnancy screening and
the recent visit to the outpatient clinic (median 19 (IQR 16–21) vs.
17 (IQR 13–20) years; p = 0.03).
We also compared the AST to platelet ratio (APRI) score
between the excluded and study patients, but no difference was
found. No F3–F4 ﬁbrosis patients were identiﬁed in the excluded
cases (data not shown).
3.2. Association between HBV DNA and cirrhosis
3.2.1. Historic sample
To explore the association between historic viral DNA and the
diagnosis of severe ﬁbrosis or cirrhosis (F3–F4 ﬁbrosis) at the studyvisit, we did an analysis adjusted by differences in follow-up time.
Patients were stratiﬁed into four categories based on the viral DNA
at the time of HBV diagnosis (Table 2). More patients with
undetectable or low HBV DNA (<2000 IU/ml) than with
intermediate or high viral DNA (>2000 IU/ml) were diagnosed
with F3–F4 ﬁbrosis (11 patients vs. 3 patients; p = 0.62).
At the time of recruitment into this study, it appeared that four
patients had died. These patients had to be excluded due to
national ethical constraints. Hypothesizing that F3–F4 ﬁbrosis
with complications led to their deaths, they were assigned to the
high viral DNA group and the number of cases in the high viral DNA
group with F3–F4 ﬁbrosis increased from one (6%) to ﬁve (25%).
However, this did not affect the main ﬁnding of the study being
that HBV DNA was associated with ﬁbrosis progression (cases of
F3–F4 ﬁbrosis in the undetectable and low viral DNA versus
intermediate and high viral DNA would be 11 patients vs.
7 patients; p = 0.21).
Contrary to HBV DNA, more patients with HBsAg levels
above than below 1000 IU/ml in the historic sample were
diagnosed with severe ﬁbrosis or cirrhosis (10 patients vs.
4 patients; p = 0.09). In both the univariable and multivariable
analyses, there was no signiﬁcant association between F3–F4
ﬁbrosis and viral DNA or the quantitative HBsAg level
(Table 2).
Table 1
Patient characteristics
Patients included, N 119
Clinical parameters
Age at pregnancy screening, years, median (IQR) 28 (22–33)
Follow-up time, years, median (IQR)a 17 (13–20)
Diabetes, n (%) 7 (6)
BMI, kg/m2, median (IQR) 29 (26–32)
Smoking, n (%)b 18 (15)
Alcohol consumption, n (%)c 13 (11)
Illicit drug abuse, n (%)d 1 (1)
Country of origin, n (%)
Turkey 34 (29)
Ghana 32 (27)
Surinam 22 (19)
Morocco 21 (18)
Other 10 (8)
Genotype, n (%)
A 11 (9)
B 1 (1)
D 21 (18)
E 14 (12)
Indeterminate 72 (61)
Historic virological parameters
HBeAg-positive, n (%) 7 (6)
Log HBV DNA, IU/ml, median (IQR) 2.5 (1.9–3.4)
Log quantitative HBsAg level, IU/ml, median (IQR) 4.2 (3.6–4.5)
Current virological parameters
HBeAg-positive, n (%) 0 (0)
Log HBV DNA, IU/ml, median (IQR) 2.4 (1.3–3.5)
Log quantitative HBsAg level, IU/ml, median (IQR) 3.0 (0.0–4.0)
Current biological parameters, median (IQR)e
ALT, IU/l 18 (15–24)
AST, IU/l 17 (13–23)
Thrombocytes, 109/l 245 (197–281)
Prothrombin time, s 13.1 (12.8–13.5)
Alpha-fetoprotein, mg/l 2.7 (1.9–3.7)
IQR, interquartile range; BMI, body mass index; HBeAg, hepatitis B e antigen; HBV,
hepatitis B virus; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase;
AST, aspartate aminotransferase.
a Follow-up time was deﬁned as the time between pregnancy screening and the
study visit.
b Smoking was deﬁned as the inhalation of one or more tobacco products per day.
c Alcohol consumption was deﬁned as more than one alcohol containing unit per
week.
d Illicit drug abuse was deﬁned as the consumption of mood-altering substances.
e Reference values: ALT <30 IU/L and AST <35 IU/L.
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Next, we explored the association between the current HBV
DNA and quantitative HBsAg level and the diagnosis of severeTable 2
Relative risks of severe ﬁbrosis or cirrhosis by historic parametersa
Characteristics of contacts Total, n F3–F4 cases, n (%
HBV DNAc
Undetectable 22 4 (18.2) 
Low 65 7 (10.8) 
Intermediate 16 2 (12.5) 
High 16 1 (6.2) 
Quantitative HBsAg level, IU/ml
>1000 101 10 (9.9) 
<1000 18 4 (22.2) 
Country of origin
Morocco 21 1 (4.8) 
Turkey 34 3 (8.8) 
Ghana 32 4 (12.5) 
Surinam 22 4 (18.2) 
Other 10 2 (20.0) 
RR, relative risk; CI, conﬁdence interval; HBV, hepatitis B virus; HBsAg, hepatitis B sur
a Relative risks are adjusted for follow-up period.
b All variables tested at univariable level were included in a direct multivariable an
c HBV DNA categories: undetectable viral DNA, <20 IU/ml; low viral DNA, between 20 
DNA, >20 000 IU/ml.ﬁbrosis or cirrhosis. At current evaluation, one patient (0.8%) with
F2 ﬁbrosis in the intermediate viral DNA group had a hepatitis D
co-infection. Compared with an undetectable HBV DNA in the
current sample, HBV DNA was not a predictor of severe ﬁbrosis or
cirrhosis (low viral DNA group, odds ratio (OR) 1.9, 95% CI 0.5–8.0;
intermediate viral DNA group, OR 1.8, 95% CI 0.4–9.0) (Table 3).
Similarly, a quantitative HBsAg level of >1000 IU/ml was not
associated with F3–F4 ﬁbrosis (OR 1.4, 95% CI 0.5–4.3). In the
multivariable analysis, alcohol consumption, AST level more than
0.5 times the upper limit of normal (ULN), and a prolonged
prothrombin time were independent predictors of F3–F4 ﬁbrosis
(alcohol consumption, OR 6.4, 95% CI 1.3–30.1; AST >0.5 ULN, OR
15.4, 95% CI 1.9–122.6; prothrombin time >13 s, OR 12.0, 95% CI
1.2–120.4) (Table 3).
4. Discussion
In contrast to the Asian studies that have shown a relationship
between HBV DNA and the development of severe liver ﬁbrosis or
cirrhosis (F3–F4), the main results of the present study identiﬁed
no such association in treatment-naı¨ve non-Asian women with
chronic HBV infection. Moreover, after a median of 17 years since
pregnancy screening, only a small number of these asymptomatic
HBV-infected non-Asian women had developed severe ﬁbrosis or
cirrhosis. Finally, this study showed that only alcohol consump-
tion, AST level, and an increased prothrombin time were predictors
of the presence of severe ﬁbrosis and cirrhosis (F3–F4).
Interestingly, we found that the number of patients with severe
ﬁbrosis to cirrhosis was higher in the group with HBV DNA <2000
IU/ml compared to the group with HBV DNA >2000 IU/ml (11 vs.
3 patients). One explanation for this ﬁnding is the difference in
alcohol consumption between the two groups favouring those
patients with an HBV DNA <2000 IU/ml. Alternatively, factors such
as a difference in hepatic steatosis among the viral DNA groups
might also have contributed to this ﬁnding. HDV co-infection was
not attributed to this difference since only one patient with a viral
DNA >2000 IU/ml (and F2 ﬁbrosis) had an HDV co-infection.
Our study ﬁndings are in contrast with data from other studies.
A REVEAL-HBV study showed an increasing risk of the develop-
ment of cirrhosis with increasing baseline HBV DNA.5 However,
that study population comprised only Asian patients with an HBV
genotype distribution assumed to be B and C. Our data are also in
contrast to those of the study of Zacharakis et al. in native Greek
patients with predominantly genotype D, who prospectively) Univariable analysis,
RR (95% CI)
Multivariable analysis,b
RR (95% CI)
1 (reference) 1 (reference)
0.5 (0.2–1.6) 0.6 (0.2–1.8)
0.7 (0.1–3.2) 0.9 (0.2–4.4)
0.3 (0.0–2.4) 0.3 (0.1–2.4)
1 (reference) 1 (reference)
0.4 (0.2–1.1) 0.4 (0.1–1.1)
1 (reference) 1 (reference)
1.6 (0.2–14.5) 1.6 (0.2–12.9)
2.5 (0.3–21.1) 3.1 (0.5–20.1)
3.3 (0.4–26.8) 3.4 (0.5–24.4)
4.3 (0.4–42.9) 3.6 (0.4–36.3)
face antigen.
alysis.
and 2000 IU/ml; intermediate viral DNA, between 2000 and 20 000 IU/ml; high viral
Table 3
Prevalence of severe ﬁbrosis to cirrhosis by characteristics
Characteristics
of contacts
Total,
n
F3–F4
cases,
n (%)
Univariable
analysis,
OR (95% CI)
Multivariable
analysis,
OR (95% CI)
Age at enrolment, years
45 66 8 (12.1) 1 (reference)
>45 53 6 (11.3) 0.9 (0.3–2.9)
Country of origin
Turkey 34 3 (8.8) 1 (reference)
Ghana 32 4 (12.5) 1.5 (0.3–7.2)
Surinam 22 4 (18.2) 2.3 (0.5–11.4)
Morocco 21 1 (4.8) 0.5 (0.1–5.3)
Other 10 2 (20.0) 2.6 (0.4–18.1)
Smoking
No 101 11 (10.8) 1 (reference)
Yes 18 3 (16.7) 1.4 (0.4–5.6)
Alcohol consumption
No 84 7 (8.3) 1 (reference) 1 (reference)
Yes 35 7 (20.0) 2.8 (0.9–8.5) 6.4 (1.3–30.1)a
BMI, kg/m2
25 22 3 (13.6) 1 (reference)
>25 97 11 (11.3) 0.8 (0.2–3.2)
Diabetes
No 112 12 (10.7) 1 (reference)
Yes 7 2 (28.6) 3.3 (0.6–19.1)
ALT
0.5  ULN 63 7 (11.1) 1 (reference)
>0.5  ULN 56 7 (12.5) 1.1 (0.4–3.5)
AST
0.5  ULN 112 11 (9.8) 1 (reference) 1 (reference)
>0.5  ULN 7 3 (42.9) 6.9 (1.4–34.8)a 15.4 (1.9–122.6)a
Thrombocytesb
<150  109/l 3 0 (0) 1 (reference)
>150  109/l 111 13 (11.7) NA
Indeterminate 5 1 (20.0) NA
Prothrombin timeb
<13 s 41 1 (2.4) 1 (reference) 1 (reference)
>13 s 76 13 (17.1) 8.3 (1.0–65.6)a 12.0 (1.2–120.4)a
Indeterminate 2 0 (0) NA
Alpha-fetoproteinb
<9 mg/l 114 14 (12.3) 1 (reference)
>9 mg/l 5 0 (0) NA
HBV DNA groupc
Undetectable 36 3 (8.3) 1 (reference)
Low 47 7 (14.9) 1.9 (0.5–8.0)
Intermediate 28 4 (14.3) 1.8 (0.4–9.0)
High 8 0 (0.0) NA
Quantitative HBsAg level
1000 IU/ml 59 6 (10.2) 1 (reference)
>1000 IU/ml 59 8 (13.6) 1.4 (0.5–4.3)
Indeterminate 1 0 (0.0) NA
Genotype
A 11 3 (27.3) 1 (reference)
B 1 0 (0.0) NA
C 0 0 (0.0) NA
D 21 0 (0.0) NA
E 14 2 (14.3) 0.4 (0.1–3.3)
Indeterminate 72 9 (12.5) NA
OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; ALT, alanine
aminotransferase; ULN, upper limit of normal; AST, aspartate aminotransferase;
NA, not applicable; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.
a p  0.05.
b Cut-off based on reference value for parameter.
c HBV DNA categories: undetectable viral DNA, <20 IU/ml; low viral DNA,
between 20 and 2000 IU/ml; intermediate viral DNA, between 2000 and 20 000 IU/
ml; high viral DNA, >20 000 IU/ml.
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factor for liver disease progression.20
An interesting observation from our study is that patients with
low ALT levels can also be at risk of the presence of ﬁbrosis; this has
also been observed by others.21 A prospective study in India, with a
cut-off value for ALT similar to the one used in our study, showed a
comparable percentage of 14% for moderate to severe ﬁbrosis in
HBeAg-negative patients with normal ALT.21 However, the Indianstudy showed a signiﬁcant relationship between HBV DNA levels
and histological ﬁbrosis grade, which was not found in our study. A
possible explanation might be differences in other risk factors such
as alcohol consumption and smoking, as these factors were poorly
described in the Indian study. Since several studies (mainly in
patients with genotypes A, C, and D), like our study, have already
shown that patients may develop severe ﬁbrosis even with normal
ALT levels, an amendment to the currently used values for ALT and
AST21,22 should be considered in which HBeAg-negative chronic
HBV-infected patients should be referred for monitoring of disease
activity.
Our study was distinctive since a multi-ethnic group of non-
Asian women with chronic HBV was included. Furthermore, the
time between pregnancy screening and the study visit for
evaluation of liver ﬁbrosis was almost two decades and the time
between assumed infection and evaluation of liver ﬁbrosis was
four to ﬁve decades. All patients were asymptomatic and had
already experienced HBe seroconversion during the study visit.
Since a relatively small number of patients had severe ﬁbrosis or
cirrhosis after a long follow-up, we expect that the development of
liver complications will be low in these patients and therefore will
not signiﬁcantly increase during the next decades. Finally, as well
as historic HBV DNA, the quantitative HBsAg level in a historic
sample was also evaluated as a possible predictor of the
development of cirrhosis.
This study has some limitations. First, similar to the study of the
REVEAL-HBV group, no liver biopsies were performed. However,
several studies in chronic HBV patients have already shown that
LSM can reliably detect the presence of severe ﬁbrosis and
cirrhosis.23,24 Second, due to the method of recruitment, using an
opt-in procedure, a possible selection bias cannot be ruled out.
Restrictions to acquiring information about the cause of death in
the deceased patients might have resulted in a selection bias.
However, the assumption that all of these women died due to
cirrhosis with a high viral DNA did not have any impact on our
results. Finally, although the calculated necessary number of study
patients was reached, a number of women had to be excluded due
to unsuccessful LSM because of obesity, resulting in a smaller
sample size than planned.
In summary, we conclude that in non-Asian women with
chronic HBV infection, neither the historic nor the current viral
HBV DNA, or the quantitative HBsAg level is associated with the
development of HBV-related cirrhosis. A larger study in non-Asian
women should be performed to conﬁrm these ﬁndings.
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